Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 5604891, 16 pages
https://doi.org/10.1155/2017/5604891
Review Article

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

1Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
2CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France
3Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France
4CHU Nantes, Hotel Dieu, Nantes, France
5Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, USA

Correspondence should be addressed to Stéphane Birklé

Received 15 August 2016; Revised 18 November 2016; Accepted 8 December 2016; Published 5 January 2017

Academic Editor: Julie Boucau

Copyright © 2017 Julien Fleurence et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Julien Fleurence, Sophie Fougeray, Meriem Bahri, et al., “Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy,” Journal of Immunology Research, vol. 2017, Article ID 5604891, 16 pages, 2017. doi:10.1155/2017/5604891